Estimating unknown parameters in haemophilia using expert judgement elicitation

The increasing attention to healthcare costs and treatment efficiency has led to an increasing demand for quantitative data concerning patient and treatment characteristics in haemophilia. However, most of these data are difficult to obtain. The aim of this study was to use expert judgement elicitation (EJE) to estimate currently unavailable key parameters for treatment models in severe haemophilia A. Using a formal expert elicitation procedure, 19 international experts provided information on (i) natural bleeding frequency according to age and onset of bleeding, (ii) treatment of bleeds, (iii) time needed to control bleeding after starting secondary prophylaxis, (iv) dose requirements for secondary prophylaxis according to onset of bleeding, and (v) life‐expectancy. For each parameter experts provided their quantitative estimates (median, P10, P90), which were combined using a graphical method. In addition, information was obtained concerning key decision parameters of haemophilia treatment. There was most agreement between experts regarding bleeding frequencies for patients treated on demand with an average onset of joint bleeding (1.7 years): median 12 joint bleeds per year (95% confidence interval 0.9–36) for patients ≤18, and 11 (0.8–61) for adult patients. Less agreement was observed concerning estimated effective dose for secondary prophylaxis in adults: median 2000 IU every other day The majority (63%) of experts expected that a single minor joint bleed could cause irreversible damage, and would accept up to three minor joint bleeds or one trauma related joint bleed annually on prophylaxis. Expert judgement elicitation allowed structured capturing of quantitative expert estimates. It generated novel data to be used in computer modelling, clinical care, and trial design.

[1]  C. Hermans,et al.  Management of acute haemarthrosis in haemophilia A without inhibitors: literature review, European survey and recommendations , 2011, Haemophilia : the official journal of the World Federation of Hemophilia.

[2]  D. Lewandowski,et al.  A modeling approach to evaluate long-term outcome of prophylactic and on demand treatment strategies for severe hemophilia A , 2011, Haematologica.

[3]  L. Mantovani,et al.  A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study) , 2011, Journal of thrombosis and haemostasis : JTH.

[4]  Susie ElSaadany,et al.  Expert Elicitation for the Judgment of Prion Disease Risk Uncertainties , 2011, Journal of toxicology and environmental health. Part A.

[5]  Sindhu R Johnson,et al.  Methods to elicit beliefs for Bayesian priors: a systematic review. , 2010, Journal of clinical epidemiology.

[6]  A. Miners,et al.  Revisiting the cost‐effectiveness of primary prophylaxis with clotting factor for the treatment of severe haemophilia A , 2009, Haemophilia : the official journal of the World Federation of Hemophilia.

[7]  Roger M. Cooke,et al.  Fifteen years of expert judgement at TUDelft , 2008 .

[8]  Alan R. Cohen,et al.  Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. , 2007, The New England journal of medicine.

[9]  S. Darby,et al.  Mortality rates, life expectancy, and causes of death in people with hemophilia A or B in the United Kingdom who were not infected with HIV. , 2007, Blood.

[10]  A. Abad,et al.  Recent developments in clinimetric instruments , 2006, Haemophilia : the official journal of the World Federation of Hemophilia.

[11]  L. Valentino,et al.  Life expectancy in hemophilia outcome , 2006, Journal of thrombosis and haemostasis : JTH.

[12]  F. Rosendaal,et al.  Mortality and causes of death in patients with hemophilia, 1992–2001: a prospective cohort study 1 , 2006, Journal of thrombosis and haemostasis : JTH.

[13]  P. Giangrande,et al.  Clinical outcomes and resource utilization associated with haemophilia care in Europe , 2002, Haemophilia : the official journal of the World Federation of Hemophilia.

[14]  J. Evans,et al.  Use of expert judgment in exposure assessment. Part I. Characterization of personal exposure to benzene , 2001, Journal of Exposure Analysis and Environmental Epidemiology.

[15]  Sultan,et al.  Epidemiological survey of the orthopaedic status of severe haemophilia A and B patients in France , 2000, Haemophilia : the official journal of the World Federation of Hemophilia.

[16]  C. Sabin,et al.  Assessing the effectiveness and cost‐effectiveness of prophylaxis against bleeding in patients with severe haemophilia and severe von Willebrand's disease , 1998, Journal of internal medicine.

[17]  S. Teutsch,et al.  Episodic versus prophylactic infusions for hemophilia A: a cost-effectiveness analysis. , 1996, The Journal of pediatrics.

[18]  H. Pettersson,et al.  A longitudinal study of orthopaedic outcomes for severe factor‐VIII‐deficient haemophiliacs , 1994, Journal of internal medicine.

[19]  J S Evans,et al.  Use of probabilistic expert judgment in uncertainty analysis of carcinogenic potency. , 1994, Regulatory toxicology and pharmacology : RTP.